For an adult with type 2 diabetes needing additional glucose lowering, should I use Januvia (sitagliptin) or Farxiga (dapagliflozin)?

Farxiga (Dapagliflozin) is Superior to Januvia (Sitagliptin) for Type 2 Diabetes

For adults with type 2 diabetes needing additional glucose lowering, choose Farxiga (dapagliflozin) over Januvia (sitagliptin) because it provides superior cardiovascular and renal protection—reducing mortality, heart failure hospitalizations, and kidney disease progression—while achieving comparable or better glycemic control.

Why Farxiga Wins: Mortality and Morbidity Benefits

The fundamental difference between these medications lies in their impact on what matters most: whether patients live longer and stay out of the hospital.

Cardiovascular and Renal Protection (Farxiga's Advantage)

Farxiga has FDA-approved indications that Januvia lacks 1:

• Reduces cardiovascular death in patients with established cardiovascular disease
• Reduces heart failure hospitalizations by 26% (HR 0.74) in patients with or without diabetes 2
• Slows chronic kidney disease progression by 44% (HR 0.56), including sustained eGFR decline ≥50%, end-stage kidney disease, or renal/CV death 3
• Reduces all-cause mortality by 31% (HR 0.69) in patients with chronic kidney disease 3

Januvia has none of these mortality or morbidity benefits. It only lowers blood sugar—nothing more 4.

Guideline Recommendations Strongly Favor SGLT2 Inhibitors

The 2024 ADA Standards of Care explicitly prioritize SGLT2 inhibitors like Farxiga over DPP-4 inhibitors like Januvia 5:

• For patients with heart failure: SGLT2 inhibitor recommended (Strong Recommendation, High-Quality Evidence) 5
• For patients with CKD (eGFR 20-60 or albuminuria): SGLT2 inhibitor should be used for slowing CKD progression and reducing CV events 5
• For patients with established CV disease: SGLT2 inhibitors reduce hospitalization for heart failure and death 3

The 2024 American College of Physicians guideline goes further: They recommend AGAINST adding DPP-4 inhibitors (like Januvia) to metformin to reduce morbidity and mortality (Strong Recommendation, High-Quality Evidence) 6. In contrast, they strongly recommend adding SGLT2 inhibitors or GLP-1 agonists 6.

Glycemic Control: Farxiga is Non-Inferior or Better

While cardiovascular and renal benefits should drive your decision, Farxiga also achieves comparable or superior glucose lowering:

Head-to-Head Comparison Data

In the CompoSIT-R trial comparing these drugs directly in patients with mild renal insufficiency 7, 8:

• Januvia reduced HbA1c by 0.48%
• Farxiga reduced HbA1c by 0.36%
• Januvia showed slightly better glycemic control in this specific population with eGFR 60-90

However, in other real-world studies 9:

• Farxiga reduced HbA1c by 1.05% at 24 months
• Januvia reduced HbA1c by 0.81%
• Farxiga produced superior improvements in systolic BP (-5.5 mmHg), liver enzymes, proteinuria, and insulin resistance

The Glycemic Control Context

The small glycemic advantage of Januvia (0.1-0.2% HbA1c) is clinically insignificant when weighed against Farxiga's massive mortality and morbidity benefits. You're trading a trivial glucose difference for life-saving cardiovascular and renal protection.

Practical Prescribing Algorithm

Choose Farxiga if ANY of the following apply:

1. Established cardiovascular disease (prior MI, stroke, PAD)
2. Heart failure (any ejection fraction)
3. Chronic kidney disease (eGFR 25-90 or albuminuria)
4. Multiple CV risk factors (age >50 with hypertension, dyslipidemia, smoking)
5. Patient desires weight loss (Farxiga causes 2-3 kg weight loss vs. weight neutral with Januvia)

Choose Januvia ONLY if:

1. eGFR <25 mL/min/1.73 m² (Farxiga initiation not recommended) 1
2. History of recurrent genital mycotic infections unresponsive to treatment
3. Patient refuses SGLT2 inhibitor after shared decision-making
4. Active diabetic foot ulcers or severe peripheral vascular disease (relative caution with SGLT2i) 2

Dosing Specifics

Farxiga 1:

• Start 5 mg daily for glycemic control; increase to 10 mg if needed
• Use 10 mg daily for CV/renal protection (regardless of glucose control)
• Can use down to eGFR ≥25; continue if eGFR falls below 25 while on treatment
• Withhold 3 days before major surgery

Januvia 4:

• 100 mg daily if eGFR ≥45
• 50 mg daily if eGFR 30-44
• 25 mg daily if eGFR <30

Safety Considerations

Farxiga Adverse Effects 2, 3:

• Genital mycotic infections (10-15% in women, lower in men)—manageable with antifungals, rarely require discontinuation
• Euglycemic DKA (rare)—withhold during illness, fasting, or surgery
• Volume depletion—assess volume status before starting; reduce diuretics if needed
• Temporary eGFR decline (up to 15%)—typically resolves in 1-3 months

Januvia Adverse Effects 4:

• GI complaints (abdominal pain, nausea, diarrhea up to 16%)
• Hypoglycemia risk minimal as monotherapy
• Generally well-tolerated

Both drugs have acceptable safety profiles, but Farxiga's adverse effects are manageable and far outweighed by its mortality benefits.

Common Pitfalls to Avoid

1. Don't choose Januvia just because it's "easier"—the mortality data for Farxiga is overwhelming
2. Don't wait for complications to develop—start Farxiga early for CV/renal protection even if glucose is controlled 3
3. Don't stop Farxiga if eGFR drops slightly—this is expected and reversible 3
4. Don't avoid Farxiga in elderly patients—benefits extend to age ≥65 8
5. Don't use Januvia thinking it's "safer for kidneys"—Farxiga actually protects kidneys better 3, 4

The Bottom Line

Farxiga reduces the risk of death, heart attacks, strokes, heart failure hospitalizations, and kidney failure. Januvia does not. While Januvia may lower glucose slightly more in select populations, this difference is trivial compared to Farxiga's life-saving benefits. Unless there's a specific contraindication, Farxiga is the clear choice for adults with type 2 diabetes needing additional glucose lowering.